# Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

> **NCT00486356** · PHASE1 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 46 (actual)

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Gastric Cancer
- Liver Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** capecitabine
- **DRUG:** carboplatin
- **DRUG:** epirubicin hydrochloride
- **GENETIC:** microarray analysis
- **GENETIC:** polymorphism analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00486356
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-01
- **Primary completion:** 2010-01-01
- **Final completion:** 2010-01-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486356, "Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00486356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*